Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A

NCT07229807 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2025-12-16

No results posted yet for this study

Summary

This trial is conducted in China. The aim of the trial is to investigate safety and efficacy of ZSP1273 granules

Conditions

Interventions

DRUG

ZSP1273

Oral

DRUG

Oseltamivir

Oral

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-22
Primary Completion
2025-12-17
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229807 on ClinicalTrials.gov